VWF also influences secondary hemostasis by stabilizing factor VIII (FVIII) in the circulation.5, 6, 7Although VWD is mainly characterized by mucocutaneous bleeding, the phenotype and severity of bleeds vary between individuals and by VWD type.8If not adequately controlled, bleeds in patients with VWD can cause long-term complications, such as arthropathy and anemia5, 9and lower health-related quality of life, especially in the most severely affected patients.10, 11. This evidence concerns the gene VWF and von Willebrand disease (hereditary or acquired).